Abstract
Inhibiting Extracellular Vesicle Trafficking as Antiviral Approach to Corona Virus Disease 2019 Infection.
Highlights
Enrica Urciuoli and Barbara Peruzzi*Multifactorial and Complex Diseases Research Area, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy
At the end of 2019, some pneumonia cases with unknown aetiology were reported by Chinese health authorities in the city of Wuhan (Hubei province, China)
On February 2020, the World Health Organization announced that the respiratory disease caused by 2019-nCoV had been officially named COVID-19 (Corona Virus Disease 2019) and the virus responsible for the COVID-19 cases was classified and designated as SARS-CoV-2 (Coronaviridae Study Group of the International Committee on Taxonomy of Viruses, 2020)
Summary
Multifactorial and Complex Diseases Research Area, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy. Inhibiting Extracellular Vesicle Trafficking as Antiviral Approach to Corona Virus Disease 2019 Infection
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
